CSIMarket


Amgen Inc   (NASDAQ: AMGN)
Other Ticker:  
 

Amgen Inc

AMGN's Fundamental analysis








Amgen Inc 's sales fell in the first quarter of 2025 from the same quarter a year ago.

Biotechnology & Pharmaceuticals industry recorded growth of revenues by 12.78 %

Amgen Inc realized net income compared to net loss a year ago in first quarter of 2025

More on AMGN's Growth


Amgen Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Amgen Inc PEG ratio is at 3.65
Company
PE TTM   
Industry
-
PE TTM    
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.37.


More on AMGN's Valuation
 
 Total Debt (Millions $) 57,381
 Dividend TTM ($) 8.95 $
 Dividend Yield TTM (%) 3 %
 Revenue/Employee (TTM) $ -
 Net Income/Employee (TTM) $ 247,208
 Receivable Turnover (TTM) -
 Tangible Book Value (Per Share $)

Amgen Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Amgen Inc PEG ratio is at 3.65
Company
PE TTM   
Industry
-
PE TTM    
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.37.